(CIX: WRAL30)  1,164.94  down arrow-2  (-0.17 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: Apple)  123.03  down arrow-1.21  (-0.97 %)  Updated: 02:54 PM EDT, Mar 27 2015
(NY: QUINTILES)  67.23  up arrow+0.94  (1.42 %)  Updated: 02:53 PM EDT, Mar 27 2015
(OP: BASF SE)  100.54  up arrow+0.91  (0.92 %)  Updated: 02:49 PM EDT, Mar 27 2015
(NQ: BioCryst)  7.96  down arrow-0.15  (-1.85 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: BioDelivery)  13.81  up arrow+0.06  (0.44 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: CEMP)  31.58  up arrow+0.59  (1.9 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: Cisco Systems)  27.16  up arrow+0.07  (0.24 %)  Updated: 02:54 PM EDT, Mar 27 2015
(NQ: Cree)  34.19  down arrow-0.83  (-2.36 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: DARA)  0.80    (0.15 %)  Updated: 02:50 PM EDT, Mar 27 2015
(NY: EMC CORPORATION)  25.17  down arrow-0.64  (-2.48 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: Extreme Networks)  3.07  down arrow-0.03  (-0.97 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: FB)  83.50  up arrow+0.49  (0.59 %)  Updated: 02:54 PM EDT, Mar 27 2015
(NY: GLAXOSMITHKLINE)  47.01  up arrow+0.35  (0.75 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: GOOG)  551.27  down arrow-3.9  (-0.7 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NY: IBM)  160.03  down arrow-0.56  (-0.35 %)  Updated: 02:54 PM EDT, Mar 27 2015
(NY: LH)  127.05  up arrow+1.25  (0.99 %)  Updated: 02:53 PM EDT, Mar 27 2015
(OP: Lenovo Group)  28.54  down arrow-0.55  (-1.87 %)  Updated: 02:18 PM EDT, Mar 27 2015
(NY: MRK)  57.80  up arrow+0.2  (0.35 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: Microsoft Corp)  40.89  down arrow-0.32  (-0.78 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: NTAP)  35.01  down arrow-0.54  (-1.52 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NY: NOVARTIS AG)  100.35  up arrow+0.79  (0.79 %)  Updated: 02:54 PM EDT, Mar 27 2015
(OP: Novozymes A/S)  45.78  down arrow-0.33  (-0.72 %)  Updated: 02:38 PM EDT, Mar 27 2015
(NY: PFIZER)  34.51  up arrow+0.35  (1.02 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: Pozen)  7.65  up arrow+0.04  (0.53 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NY: RED HAT)  76.08  up arrow+0.72  (0.96 %)  Updated: 02:54 PM EDT, Mar 27 2015
(NQ: BBRY)  9.48  up arrow+0.18  (1.94 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: Salix)  172.71  up arrow+0.08  (0.05 %)  Updated: 02:53 PM EDT, Mar 27 2015
(NQ: SQI)  17.17  up arrow+0.14  (0.82 %)  Updated: 02:43 PM EDT, Mar 27 2015

Posts tagged “Pappas”

Updated December 9, 2014

Premium Lock VCs launch a diversity task force - years too late but better than never

The lack of diversity among the ranks of professional venture capitalists and their companies has been a disgrace for years. Finally, the National Venture Capital Association is launching a "Diversity Task Force." But like the technology industry on which it focuses, the NVCA has a lot of work to do to change its almost-all white, male labor force. By the way, a Durham VC is serving on the group.

Diversity Diversity

Updated September 3, 2014

Premium Lock Pappas to manage new venture fund from Chiesi Group

Venture Capital Durham-based venture capital firm A.M. Pappas & Associates will manage a new venture capital fund being launched by Italy-based Chiesi Ventures, the companies announced Tuesday.

Updated May 8, 2014

Premium Lock Charlotte drug firm led by former Pappas Ventures exec sells for $658M

Chelsea Therapeutics has agreed to be purchased by Danish global drug company Lundbeck for up-front cash and milestone payments to shareholders. The total depends on whether Chelsea's newly approved debut drug meets expectations when it hits the market. The buyout caps a stellar run for Joseph Oliveto, a former executive at Pappas Ventures in Durham.

Chelsea's new CEO Chelsea's new CEO

January 9, 2014

Premium Lock Facebook shares hit record; Pappas promotion; ChannelAdvisor execs on road; Google ferries workers; Samsung's new 'eye' phone

Bulldog In our Bulldog blog's regional tech and life science news update: Facebook shares are at a record high; Pappas Ventures names a new partner; ChannelAdvisor execs hit the road to talk business; Google to ferry workers to the Valley; Samsung's new phone may include eye recognition.

Updated December 11, 2013

Premium Lock Chairman and former CEO of Roche joins Pappas Ventures

Franz Humer Franz Humer, chairman and former chief executive officer of global drug giant Roche, is joining Durham-based venture capital firm Pappas Ventures as a partner and senior advisor.

Updated May 16, 2013

Premium Lock Triangle VC Pappas joins National Venture Capital Association board

Arthur Pappas Art Pappas, one of the deans of the venture capital industry in North Carolina, is among five VCs named to the board of the National Venture Capital Association.

September 19, 2012

Premium Lock CoLucid, FDA settle on next steps in migraine drug trial

CoLucid CoLucid has raised more than $41 million in venture funding since its launch in 2005. Pappas Ventures, which is based in the Triangle, launched the company. Funds raised a year ago were targeted for use in a Phase 3 trial of its lead candidate.

Updated July 23, 2012

Premium Lock Despite surge in tech startups, VCs see little chance of a 'bubble'

Venture Update With all the recent programs rolling out to support the launch and growth of new companies, funding remains scarce. If nothing else, lack of cash will keep a damper on entrepreneurs' hopes of flaming beyond control.

Updated July 20, 2012

Premium Lock VCs remain optimistic despite tough deal numbers

Venture update Two new reports on the state of venture capital paint a grim picture for deal making in North Carolina. So what's happening out there? Several VCs offer their thoughts.

Updated July 6, 2012

Premium Lock Update: Pappas raising new fund but not $300M

Pappas Ventures PEHub says veteran venture capitalist Art Pappas and colleagues at Pappas Ventures are raising a new fund. However, the size is about half what the website reported, WRAL Tech Wire is told.

Updated February 20, 2012

Premium Lock RTP startup focused on diabetes raises $2.5M

Diabetes research Lumena's investors are venture capital firms Pappas Ventures and RiverVest Venture Partners. The new capital means the company can proceed to human tests for its novel type 2 diabetes treatment, which aims to develop a pill to help patients regulate their blood sugar.

February 20, 2012

Premium Lock Triangle may draw interest from more life science investors

Venture Briefs Talk can be cheap, of course, and investors who look to Research Triangle Park have been pretty predictable over the years. But some new faces showed up at the CED Life Science Conference - and some familiar ones returned.

February 8, 2012

Premium Lock Co-founder of CoLucid Pharmaceuticals in Durham dies

CoLucid Dr. James White, a long-time pharmaceutical executive, launched CoLucid in 2005 along with Art Pappas of Pappas Ventures in Durham.

February 7, 2012

Premium Lock Startup Chimerix reports positive test news for transplant drug

Chimerix The company is studying the compound for the prevention of cytomegalovirus diseases, or CMV, in patients who have had stem cell transplants.

December 9, 2011

Premium Lock CeNeRx CEO looks for partner, gears for more clinical trials

Brain power  The Cary-based company has closed on a fundraise of $4.8 million that the company will apply to its portfolio of central nervous system drug candidates, chiefly TriRima, which is set to complete phase 2b trials early next year. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners, Pappas Ventures and Omega Funds all participated in the latest round. CeNeRx has raised more than $55 million to date.

Updated December 9, 2011

Premium Lock Cary-based CeNeRx lands $4.85M, advances Alzheimer's drug

CeNeRx Pappas Ventures is among the funders for the company that is focused on central nervous system diseases. CeNeRx also files a new drug application for a potential Alzheimer's treatment.

November 19, 2011

Premium Lock Will personalized medicine deliver on its promises?

DNA      There is no shortage of companies angling for financial backing of new therapies and diagnostics in personalized medicine. But will challenges of regulations, reimbursements, costs and technical requirements be overcome?

Updated October 11, 2011

Premium Lock Belief in biotech founder delivers big dividends for Pappas Ventures

Plexxicon CEO Peter Hirth At the Durham-based venture capital firm's annual life science symposium, guests hear the inside story about California-based Plexxikon, its $935 million acquisition and personalized medicince drive led by CEO Peter Hirth.

August 30, 2011

Premium Lock CoLucid raises $7.5M in new funding, targets $2M more

CoLucid The Durham-based startup launched by Pappas Ventures is looking for a partner to advance its lead pain reliever to Phase 3 clinical trials.

August 18, 2011

Premium Lock Durham-based CoLucid looking for drug development partners

CoLucid's pipeline The startup, which is backed by Triangle-based Pappas Ventures, receives FDA approval to proceed with Phase 3 clinical trials of lead migraine product.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith